• Stock Market Overview
  • Market Momentum
  • Market Performance
  • Top 100 Stocks
  • Today's Price Surprises
  • New Highs & Lows
  • Economic Overview
  • Earnings Within 7 Days
  • Earnings & Dividends
  • Stock Screener
  • Today's Top Stock Pick
  • All Top Stock Picks
  • Percent Change
  • Price Change
  • Range Change
  • Gap Up & Gap Down
  • Five Day Gainers
  • Pre-Market Trading
  • Post-Market Trading
  • Volume Leaders
  • Price Volume Leaders
  • Volume Advances
  • Trading Liquidity
  • Market Indices
  • S&P Indices
  • S&P Sectors
  • Dow Jones Indices
  • Nasdaq Indices
  • Russell Indices
  • Volatility Indices
  • Commodities Indices
  • US Sectors Indices
  • World Indices
  • New Recommendations
  • Top Stocks to Own
  • Top Signal Strength
  • Top Signal Direction
  • Stock Signal Upgrades
  • Stock Market Sectors
  • Major Markets Heat Map
  • Industry Rankings
  • Industry Heat Map
  • Industry Performance
  • Options Stocks by Sector
  • Options Market Overview
  • Unusual Options Activity
  • IV Rank and IV Percentile
  • Most Active Options
  • Unusual Options Volume
  • Highest Implied Volatility
  • %Change in Volatility
  • Options Volume Leaders
  • Change in Open Interest
  • %Chg in Open Interest
  • Upcoming Earnings
  • Options Strategy Indexes
  • Options Price History
  • Options Flow
  • Options Calculator
  • Options Time & Sales
  • Options Screener
  • Long Call Screener
  • Long Put Screener
  • Covered Calls
  • Married Put
  • Collar Spread
  • Bull Call Debit Spreads
  • Bear Call Credit Spreads
  • Bear Put Debit Spreads
  • Bull Put Credit Spreads
  • Short Straddle
  • Long Straddle
  • Short Strangle
  • Long Strangle
  • Long Call Butterfly
  • Short Call Butterfly
  • Long Put Butterfly
  • Short Put Butterfly
  • Short Iron Condor
  • Long Iron Condor
  • Long Call Condor
  • Long Put Condor
  • Short Call Condor
  • Short Put Condor
  • Long Call Calendar
  • Long Put Calendar
  • ETF Market Overview
  • Popular ETFs
  • Top 100 ETFs
  • Top Dividend ETFs
  • ETF Screener
  • Top ETFs to Own
  • ETFs Signal Upgrades
  • Performance
  • Funds Screener
  • Futures Market Overview
  • Long Term Trends
  • Highs & Lows
  • Futures Market Map
  • Performance Leaders
  • Most Active Futures
  • Prices by Exchange
  • Commodities Prices
  • Mini & Micro Futures
  • Trading Guide
  • Historical Performance
  • Commitment of Traders
  • Legacy Report
  • Disaggregated Report
  • Financial TFF Report
  • Contract Specifications
  • Futures Expirations
  • First Notice Dates
  • Options Expirations
  • Economic Calendar
  • Cash Markets Overview
  • Corn Indexes
  • Soybean Indexes
  • Yield Forecast Indexes
  • Euro Futures Overview
  • Power Futures
  • Carbon Futures
  • European Trading Guide
  • Forex Market Overview
  • Forex Market Map
  • Currency Converter
  • Crypto Market Overview
  • Market Capitalizations
  • Bitcoin Futures
  • Popular Cross Rates
  • Australian Dollar
  • British Pound
  • Canadian Dollar
  • Japanese Yen
  • Swiss Franc
  • Metals Rates
  • All Forex Markets
  • Popular Coins
  • Bitcoin-Cash
  • Today’s Investing Ideas
  • Top Performing Stocks
  • Top Trending Tickers
  • Barchart Screeners
  • Insider Trading Activity
  • Politician Insider Trading
  • Chart of the Day
  • Top Stock Pick
  • Futures Trading Guide
  • Biotechnology Stocks
  • Blockchain Stocks
  • Bullish Moving Averages
  • Candlestick Patterns
  • Cannabis Stocks
  • Clean Energy Stocks
  • Dividend Stocks
  • eMACD Buy Signals
  • Gold Stocks
  • Hot Penny Stocks
  • Metaverse Stocks
  • SPAC Stocks
  • Top Stocks Under $10
  • TTM Squeeze
  • Warren Buffett Stocks
  • World Markets
  • Markets Today
  • Barchart News
  • Contributors
  • Alan Brugler
  • Andrew Hecht
  • Angie Setzer
  • Darin Newsom
  • Gavin McMaster
  • Jim Van Meerten
  • Josh Enomoto
  • Oleksandr Pylypenko
  • Rich Asplund
  • Rick Orford
  • All Authors
  • All Commodities
  • Food & Beverage
  • All Financials
  • Interest Rates
  • Stock Market
  • Top Stories
  • All Press Releases
  • My Watchlist
  • My Portfolio
  • Investor Portfolio (BETA)
  • Convert Your Portfolios
  • Symbol Notes
  • Alert Center
  • Alert Templates
  • Custom Views
  • Chart Templates
  • Compare Stocks
  • Daily Prices Download
  • Historical Data Download
  • Watchlist Emails
  • Portfolio Emails
  • Investor Portfolio Emails
  • Screener Emails
  • End-of-Day My Charts
  • End-of-Day Reports
  • Organize Watchlists
  • Organize Portfolios
  • Organize Investor Portfolios
  • Organize Screeners
  • Organize My Charts
  • Site Preferences
  • Author Followings
  • Upcoming Webinars
  • Archived Webinars
  • Popular Webinars
  • Market on Close
  • Market on Close Archive
  • Site Education
  • Free Newsletters
  • Technical Indicators
  • Barchart Trading Signals
  • Time & Sales Conditions
  • Barchart Special Symbols
  • Barchart Data Fields
  • Barchart Premier
  • Barchart Plus
  • Membership Comparison
  • Barchart for Excel
  • Create Free Account
  • Price Overview
  • Performance Report
  • Interactive Chart
  • Snapshot Chart
  • Barchart Opinion
  • Trading Strategies
  • Top Trade Alerts
  • Technical Analysis
  • Trader's Cheat Sheet
  • Price History
  • Historical Data
  • News & Headlines
  • Key Statistics
  • SEC Filings
  • Stock Comparison
  • Insider Trades
  • Earnings Estimates
  • Analyst Ratings
  • Financial Summary
  • Income Statement
  • Balance Sheet

Field Trip Health Ltd (FTRP)

Fundamentals.

  • Market Capitalization, $K 49,023
  • Shares Outstanding, K 58,215
  • Annual Sales, $ 3,880 K
  • Annual Income, $ -43,630 K
  • 60-Month Beta N/A
  • Price/Sales 12.51
  • Price/Cash Flow N/A
  • Price/Book 0.92
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.75
  • Most Recent Earnings $-0.20 on 06/29/22
  • Latest Earnings Date 08/15/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A

Analyst Rating / Earnings Estimates

Current rating, earnings estimates - current qtr 06/30/22.

  • Average Estimate -0.15
  • Number of Estimates 2
  • High Estimate -0.15
  • Low Estimate -0.15
  • Prior Year -0.16
  • Growth Rate Est. (year over year) +6.25%

Price Performance

Most recent stories.

Field Trip Health Ltd. (FTRP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

– Field Trip Health & Wellness Ltd. to list on the TSX Venture Exchange, with first day of trading expected to occur on or about August 17, 2022....

Palm Beach, FL – July 27, 2022 – For years, ketamine was known for its use as an anesthetic or as a recreational drug. Its ability to provide quick and safe sedation saved many lives during the Vietnam...

/PRNewswire/ -- For years, ketamine was known for its use as an anesthetic or as a recreational drug. Its ability to provide quick and safe sedation saved many...

- First Dosings completed in Australia- Provides Update on Pending Spin-Out and Renaming to Reunion Neurosciences- Announces 5:1 Share Consolidation Ratio ...

Completed strategic review and announced intention to separate the Field Trip Discovery and Field Trip Health divisions into two independent public...

- Closing of arrangement subject to regulatory approvals, including conditional listing approval by the TSX Venture Exchange.- Closing of the arrangement...

Approves spin-out of clinics business to Field Trip Health & Wellness Ltd., pending final court approval and additional customary closing conditions...

TORONTO, June 23, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Ftrp related stocks.

Compare Symbols

Key Turning Points

Want to use this as your default charts setting, switch the market flag, want streaming chart updates, need more chart options, free barchart webinar.

We couldn’t find any results matching your search.

Please try using other words for your search or explore other sections of the website for relevant information.

We’re sorry, we are currently experiencing some issues, please try again later.

Our team is working diligently to resolve the issue. Thank you for your patience and understanding.

Field Trip Health Ltd. to Commence Trading on the NASDAQ on July 29, 2021 Under the Symbol FTRP

TORONTO , July 27, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; OTCQX: FTRPF) ("Field Trip" or the “Company”), a global leader in the development and delivery of psychedelic therapies, announced today that it has received final approval from The NASDAQ Stock Market LLC (“NASDAQ”) to list its common shares on the NASDAQ Global Select Market. The Company’s shares will begin trading at market open on Thursday, July 29, 2021 with the ticker symbol FTRP.

Hannan Fleiman, Field Trip’s President, said “Listing on the Nasdaq Global Select Market, NASDAQ’s top tier, is a mark of achievement and stature for listed companies who must meet the highest the highest financial and liquidity qualifications for inclusion. We are proud of the rapid progress we have made in a relatively short period of time and this accomplishment is a testament to the efforts of our employees and partners. We look forward to building value for our shareholders as we enter the next stage of our growth.”

Dr. Ryan Yermus , Field Trip’s Chief Clinical Officer, added, “Listing on the leading securities exchange for biotech companies will enable more investors both in the U.S. and globally to support Field Trip as we advance our ground-breaking work in the psychedelics industry. We continue to make steady progress with the development of FT-104, a novel psychedelic molecule, with GMP production underway in preparation for Phase 1 studies, and other strategic initiatives which will further strengthen our leadership position in the industry.”

The Company’s common stock will continue to trade in Canada on the Toronto Stock Exchange (TSX) under its current symbol FTRP; and concurrent with the listing of Field Trip’s common shares on NASDAQ in the US, the shares will cease to be quoted on the OTCQX. The Company has previously completed the process to ensure its shares are eligible for electronic clearing and settlement through the Depository Trust Company (DTC).

Concurrent with the listing, Ronan Levy and Ellen Lubman will join the compensation committee and Mujeeb Jafferi and Dr. Ryan Yermus will resign as directors of the Company. Mr. Jafferi and Dr. Yermus will continue to serve as Field Trip’s Chief Operating Officer and Chief Clinical Officer, respectively.

About Field Trip Health Ltd.

Field Trip is a global leader in the development and delivery of psychedelic therapies. With our Field Trip Discovery division leading the development of the next generation of psychedelic molecules and conducting advanced research on plant-based psychedelics and our Field Trip Health division building centers for psychedelic therapies opening across North America and Europe along with the digital and technological tools that will enable massive scale, we help people in need with a simple, evidence-based way to heal and heighten engagement with the world.

Learn more at https://www.meetfieldtrip.com , https://www.fieldtriphealth.com and https://www.fieldtriphealth.nl .

Follow us on Twitter and Instagram: @fieldtriphealth

To receive company updates about Field Trip and to be added to the email distribution list please sign up here .

For further information, contact Ronan Levy , Executive Chairman and a Director at Field Trip, at 1 (833) 833-1967.

Cautionary Note Regarding Forward-Looking Information.

This release includes forward-looking information within the meaning of Canadian securities laws regarding Field Trip and its business. Often but not always, forward-looking information can be identified by the use of words such as "expect", "intends", "anticipated", "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would" or "will" be taken, occur or be achieved. Such statements are based on the current expectations and views of future events of the management of Field Trip, and are based on assumptions and subject to risks and uncertainties. Although the management of Field Trip believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies, including the timing and results of its research and development programs, approval of phase 1 human trials, if any, the risk that future clinical studies may not proceed as expected or may produce unfavorable results, the opening of additional clinics, the COVID-19 epidemic, the medical clinic industry, market conditions, economic factors, management's ability to manage and to operate the business and the equity markets generally. Although Field Trip has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Field Trip does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

Neither the Toronto Stock Exchange , nor its Regulation Services Provider, nor the OTC Markets have approved the contents of this release or accept responsibility for the adequacy or accuracy of this release.

Media contacts: Rachel Moskowitz Autumn Communications 202-276-7881 [email protected]

Nick Opich / McKenna Miller KCSA Strategic Communications 212-896-1206 / 347-487-6197 [email protected]

Investor contacts: Elizabeth Barker KCSA Strategic Communications 212-896-1203 [email protected]

SOURCE Field Trip Health Ltd.

Primary Logo

In This Story

To add symbols:

  • Type a symbol or company name. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return.
  • Copy and paste multiple symbols separated by spaces.

These symbols will be available throughout the site during your session.

Your symbols have been updated

Edit watchlist.

  • Type a symbol or company name. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return.

Opt in to Smart Portfolio

Smart Portfolio is supported by our partner TipRanks. By connecting my portfolio to TipRanks Smart Portfolio I agree to their Terms of Use .

We've detected unusual activity from your computer network

To continue, please click the box below to let us know you're not a robot.

Why did this happen?

Please make sure your browser supports JavaScript and cookies and that you are not blocking them from loading. For more information you can review our Terms of Service and Cookie Policy .

For inquiries related to this message please contact our support team and provide the reference ID below.

field trip stock

Instrument Name Field Trip Health Ltd Instrument Symbol (FTRPF) Instrument Exchange OTC US

  • 3M 3-Months
  • 6M 6-Months

field trip stock

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024 .

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab) .

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

Psychedelic Spotlight

Why Field Trip Health Is Dividing in Two — and What This Means for Investors

  • Share on Facebook
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn

field trip stock

"The proposed separation will allow us to pursue a singular focus and commitment to innovation, while maintaining the current synergies of the integrated company through the collaboration agreement between Field Trip Health and Wellness and Reunion Neuroscience," says current CEO Joseph del Moral.

In a surprise move, Field Trip Health Ltd. (TSX: FTRP, Nasdaq: FTRP) announced on Thursday that they will be separating their company into two independent publicly traded entities.

Assuming the ratification of shareholders and regulatory approval, come July 2022, Field Trip Health will be no more. From its ashes will rise Reunion Neuroscience Inc, and Field Trip Health and Wellness Ltd.

Reunion will be the successor to Field Trip’s Discovery division, which was the part of the company which worked on next generation psychedelics. This includes FT-104, a psilocybin-like compound which is a prodrug to 4-HO-DiPT, and the company’s FT-200 series of psychedelics, which they call third-generation.

Once the deal is ratified, Reunion will keep Field Trip’s listing on the TSX and the Nasdaq, though it will be traded under a different ticker symbol, which has yet to be revealed. The company will have Joseph del Moral at the helm as CEO. 

Field Trip Health and Wellness, on the other hand, will inherit the company’s 12 psychedelic therapy clinics. These clinics currently use ketamine-assisted therapy to treat mental health issues like depression, and hope to use other substances such as MDMA and psilocybin once they become legalized. It will also offer clinical trial services, operate their psilocybin research center in Jamaica, and partner with Nue Life on Field Trip at Home™, a digital at-home ketamine assisted therapy program.

Field Trip Health and Wellness will have Ronan Levy as its CEO, and hopes to trade on the TSX Venture Exchange, pending approvals.

If you currently own stock of Field Trip Health, once the deal is finalized, for each share you own you will automatically receive 1 share of Reunion, and 0.86 shares of Field Trip H&W. Current shareholders of Field Trip Health will own 100% of Reunion, and 50% of Field Trip H&W. Of the remaining 50%, 10% will be owned by Reunion—so essentially current shareholders—and 40% will be held by new investors, led by the Oasis Management Company.

As for the cash positions of the two companies, Reunion will have $43 million CAD, and Field Trip H&W will have $23.7 million, $18.7 million of which comes from the above-mentioned new investors.

This move follows a strategic review of the company, which concluded that both parts of their business would be more likely to succeed if they operated independently from each other. 

In a press release, Field Trip Health gave four strategic rationales for the move. They said that following the transaction, both Field Trip H&W and Reunion will:

  • “have separate and focused management and governance best suited to each company's operational and strategic needs;
  • be able to establish distinct capital structures and capital allocation plans matched to the unique strategies and requirements of each company;
  • maintain current strategic synergies through a Collaboration Agreement, which will provide access to data, assistance in protocol development, preferential access to clinical trial sites and other benefits;
  • provide differentiated investment characteristics and a focused investment thesis for long-term investors in each company.”

Adding to this, in a conference call with investors, future Reunion CEO Joseph del Moral said, “the proposed separation will allow us to pursue a singular focus and commitment to innovation, while maintaining the current synergies of the integrated company through the collaboration agreement between Field Trip Health and Wellness and Reunion Neuroscience.”

I find this move fascinating, as it moves in precisely the opposite direction of what I expect to see in the psychedelics space in the coming months and years: consolidation.

For example, earlier this month Numinus Wellness (TSX: NUMI, OTCQX: NUMIF) announced that they are acquiring Novamind Inc. (CSE: NM, OTCQB: NVMDF) . At the time, I wrote that “in the coming months I expect to see more, perhaps many more, of such deals being announced.”

To be clear, I still expect that to be the case, which would make this current transaction the exception, not the rule. 

Nevertheless, this decision has already helped Field Trip Health and Wellness raise $18.7 million. That is an early sign that this decision may be in the best interests of its current shareholders.

_______________________________________________________________________

Interested in attending conferences where you can meet the leaders of the psychedelics industry? Join Paul Stamets, Ronan Levy (currently Executive Chairman of Field Trip Health and future CEO of Field Trip Health and Wellness) and more at Canada’s premier psychedelics conference, The Catalyst Summit . Being held in Kingston, Ontario, from May 20th-22, the Catalyst Summit is your chance to get the inside scoop on the psychedelics industry.

Purchase your tickets through Psychedelic Spotlight and receive 20% off!

But hurry, tickets will soon be sold out!

Full Disclosure: James Hallifax holds positions in MindMed, Compass Pathways, atai Life Sciences, the Horizons Psychedelic Stock Index, and the Advisor Shares Psychedelics ETF.

The views of the author are for informational purposes only, and should not be construed as financial advice, but rather his own personal opinion. Furthermore, the views of the author are not necessarily representative of Psychedelic Spotlight. His views and opinions are his own.

Leave a Reply

Your email address will not be published. Required fields are marked *

Related News

Manhattan Hospital Partners with Cybin to Provide Psychedelic Therapies to Marginalized Co

Manhattan Hospital Partners with Cybin to Provide Psychedelic Therapies to Marginalized Communities

Parents Are Open to Ketamine Therapy for Kids, Study Finds

Parents Are Very Open to Ketamine Therapy for Kids, Study Finds

Minnesota Gets Its First Psychedelic Clinic

Minnesota Gets Its First Psychedelic Medicine Clinic

field trip stock

Psychedelic Spotlight is your reliable source for the latest stories in the emerging psychedelics industry, covering breakthrough discoveries, investor news and cultural reform.

  • Advertise With Us
  • Privacy Policy
  • Terms and Conditions
  • Conferences

field trip stock

Get a roundup of Psychedelic news stories in your inbox

By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.

Advanced search

English (USA)

English (UK)

English (UK)

English (Canada)

English (Canada)

English (India)

English (India)

Deutsch (Deutschland)

Deutsch (Deutschland)

Deutsch (Österreich)

Deutsch (Österreich)

Deutsch (Schweiz)

Deutsch (Schweiz)

Español

Français (France)

Français (Suisse)

Français (Suisse)

Italiano

Nederlands (Nederland)

Nederlands (België)

Nederlands (België)

  • Top Capitalization
  • United States
  • North America
  • Middle East
  • Sector Research
  • Earnings Calendar
  • Equities Analysis
  • Most popular
  • NIPPON ACTIVE VALUE FUND PLC
  • TESLA, INC.
  • AMD (ADVANCED MICRO DEVICES)
  • NVIDIA CORPORATION
  • RHEINMETALL AG
  • Index Analysis
  • Indexes News
  • EURO STOXX 50
  • Currency Cross Rate
  • Currency Converter
  • Forex Analysis
  • Currencies News
  • Precious metals
  • Agriculture
  • Industrial Metals
  • Livestock and Cattle
  • CRUDE OIL (WTI)
  • CRUDE OIL (BRENT)

field trip stock

  • Developed Nations
  • Emerging Countries
  • South America
  • Analyst Reco.
  • Capital Markets Transactions
  • New Contracts
  • Profit Warnings
  • Appointments
  • Press Releases
  • Security Transactions
  • Earnings reports
  • New markets
  • New products
  • Corporate strategies
  • Legal risks
  • Share buybacks
  • Mergers and acquisitions
  • Call Transcripts
  • Currency / Forex
  • Commodities
  • Cryptocurrencies
  • Interest Rates
  • Asset Management
  • Climate and ESG
  • Cybersecurity
  • Geopolitics
  • Central Banks
  • Private Equity
  • Business Leaders
  • All our articles
  • Most Read News
  • All Analysis
  • Satirical Cartoon
  • Today's Editorial
  • Crypto Recap
  • Behind the numbers
  • All our investments
  • Asia, Pacific
  • Virtual Portfolios
  • USA Portfolio
  • European Portfolio
  • Asian Portfolio
  • My previous session
  • My most visited
  • Dividend Aristocrats
  • Undervalued stocks
  • Trend-Following Stocks
  • Pricing Power
  • Ageing Population
  • US Basketball
  • Europe's family businesses
  • Unusual volumes
  • New Historical Highs
  • New Historical Lows
  • Top Fundamentals
  • Sales growth
  • Earnings Growth
  • Profitability
  • Rankings Valuation
  • Enterprise value
  • Top Consensus
  • Analyst Opinion
  • Target price
  • Estimates Revisions
  • Top ranking ESG
  • Environment
  • Visibility Ranking
  • Stock Screener Home
  • Circular economy
  • Strategic Metals
  • Place your bets
  • Oversold stocks
  • Overbought stocks
  • Close to resistance
  • Close to support
  • Accumulation Phases
  • Most volatile stocks
  • Top Investor Rating
  • Top Trading Rating
  • Top Dividends
  • Low valuations
  • All my stocks
  • Stock Screener
  • Stock Screener PRO
  • Portfolio Creator
  • Event Screener
  • Dynamic Chart
  • Economic Calendar
  • ProRealTime Trading
  • Our subscriptions
  • Our Stock Picks
  • Thematic Investment Lists

field trip stock

Field Trip Health Ltd. Stock Other OTC

Ca31656r1029, pharmaceuticals, chart field trip health ltd., latest news about field trip health ltd., analyst recommendations on field trip health ltd., press releases field trip health ltd., company profile, sector other pharmaceuticals.

  • Stock Market
  • FTRPF Stock

IMAGES

  1. Royalty Free Field Trip Pictures, Images and Stock Photos

    field trip stock

  2. Group Of Children On A Field Trip Stock Photo

    field trip stock

  3. Students Outside On A Field Trip Stock Photo

    field trip stock

  4. Group of Student are in a Field Trip Stock Photo

    field trip stock

  5. Royalty Free Field Trip Pictures, Images and Stock Photos

    field trip stock

  6. 123,742 Field Trip Stock Photos

    field trip stock

VIDEO

  1. Vermont winter road trip stock footage

  2. Road Trip

  3. TCOM, Trip.com Group Limited, 2024-04-01, stock prices dynamics, stock of the day

  4. Easy trip planners share news,easy trip planners share target,easy trip planners share latest news

  5. BEST TOURISM STOCKS IN INDIA●EASY TRIP●THOMAS COOK SHARE●IRCTC●INDIAN HOTELS @ STOCK MARKET PLANNER

  6. easy trip share latest news

COMMENTS

  1. Field Trip Health (FTRP) Stock Price, News & Analysis

    Field Trip Health's stock reverse split before market open on Wednesday, August 17th 2022. The 1-5 reverse split was announced on Wednesday, August 17th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, August 17th 2022. An investor that had 100 shares of stock prior to the reverse split would ...

  2. Field Trip Health Stock Debuts, Adds To Psychedelic Stocks On Nasdaq

    Field Trip Health stock reversed higher to close up 1.8% at 5.85 in the stock market today. Compass edged up 0.3%. MindMed fell 2.3%. Atai, which is backed by billionaire investor Peter Thiel ...

  3. FTHWF Stock Price

    FTHWF | Complete Field Trip Health & Wellness Ltd. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

  4. Field Trip Health & Wellness Ltd. (FTHWF) Stock Price, Quote, News

    A high-level overview of Field Trip Health & Wellness Ltd. (FTHWF) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

  5. Field Trip Health (FTRPF) Stock Price, News & Analysis

    Field Trip Health (FTRPF) Stock Price, News & Analysis. Ad Vertical Research Advisory. VRA Portfolio net profits of 1,918.59% since 10/2022. The VRA Investing System has enabled us to beat the markets 17 out of 20 years (85% WIN STREAK over two decades), since founding the VRA in 2003.

  6. Ketamine Clinic Company Field Trip Health Debuts On Nasdaq

    Field Trip, which has a $329 million market cap, runs a chain of six swanky ketamine clinics across the U.S. and Canada, with locations in Atlanta, Chicago, Houston, Los Angeles, New York and Toronto.

  7. Field Trip Health & Wellness Ltd. Stock price

    Field Trip Health & Wellness Ltd. (TSXV:FTHWF) added to S&P Global BMI Index. 22-08-17. CI. Field Trip Health & Wellness Ltd. announced that it has received CAD 19.97961 million in funding from Reunion Neuroscience Inc., Oasis Management Company Ltd. 22-08-10.

  8. Field Trip Health (FTHWF) Stock Price, Quote, News & History

    Field Trip Health (FTHWF) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

  9. FTRP

    Field Trip Health Ltd stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. ... Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. Results are interpreted as buy, sell or hold signals, each with numeric ...

  10. Field Trip Health Ltd. to Commence Trading on the NASDAQ on July 29

    --Field Trip Health Ltd., a global leader in the development and delivery of psychedelic therapies, announced today that it has received final approval from The NASDAQ Stock Market LLC to list its ...

  11. Field Trip Health (FTRP) Stock Price, News & Analysis

    Field Trip Health's stock was trading at C$1.09 at the beginning of the year. Since then, FTRP stock has increased by 0.0% and is now trading at C$1.09. View the best growth stocks for 2024 here.

  12. Field Trip Announces Closing of Plan of Arrangement and $19.9 Million

    - Field Trip Health Ltd. has been renamed "Reunion Neuroscience Inc." and remains listed on the NASDAQ Stock Market and Toronto Stock Exchange under the ticker symbol "FTRP" with such ticker ...

  13. FTHWF: Field Trip Health & Wellness Ltd Stock Price Quote

    Stock analysis for Field Trip Health & Wellness Ltd (FTHWF:US) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

  14. Field Trip Health & Wellness Ltd (FTHWF) Price & News

    Get the latest Field Trip Health & Wellness Ltd (FTHWF) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment ...

  15. Field Trip Health (FTRP) Stock Price History

    Field Trip Health Ltd. engages in the development and delivery of psychedelic therapies in North America. The company operates Field Trip Health Centres that provide psychedelic therapies; offers Field Trip Digital apps; and Field Trip Discovery, a drug development division developing the next generation of psychedelic molecules. Field Trip Health Ltd. was founded in 2008 and is headquartered ...

  16. Field Trip Health Ltd (FTRPF) Stock Price and News

    Real-time Price Updates for Field Trip Health Ltd (FTRPF), along with buy or sell indicators, analysis, charts, historical performance, news and more

  17. Field Trip Health Ltd. Announces Intention to Separate the

    TORONTO, April 28, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) (the " Company "), a global leader in the development and delivery of psychedelic therapies ...

  18. Stella MSO, Inc. acquired U.S. Assets of Field Trip Health & Wellness

    Field Trip Health & Wellness Ltd. (Field Trip) is a psychedelic therapy company. The Company provides services, in person though its clinics and virtually through telemedicine, and supported by digital-based tools and communities such as Trip and Portal.

  19. Why Field Trip Health Is Dividing in Two

    If you currently own stock of Field Trip Health, once the deal is finalized, for each share you own you will automatically receive 1 share of Reunion, and 0.86 shares of Field Trip H&W. Current shareholders of Field Trip Health will own 100% of Reunion, and 50% of Field Trip H&W. Of the remaining 50%, 10% will be owned by Reunion—so ...

  20. Field Trip Health & Wellness Ltd. (FTHWF) Stock Historical Prices

    Discover historical prices for FTHWF stock on Yahoo Finance. View daily, weekly or monthly format back to when Field Trip Health & Wellness Ltd. stock was issued.

  21. Field Trip Health Ltd. Stock price Other OTC

    Analyst Recommendations on Field Trip Health Ltd. ThinkEquity Initiates Reunion Neuroscience at Buy With $5 Price Target. 23-05-01. MT. ThinkEquity Starts Reunion Neuroscience at Buy With $5 Price Target. 23-05-01. MT. Reunion Neuroscience Downgraded to Hold at Stifel GMP as it Sues a Competitor; Price Target Cut to C$1.00. 23-03-15.

  22. Field Trip Health (FTR) Stock Price, News & Analysis

    Export data to Excel for your own analysis. Start Your 30-Day Free Trial. Should You Buy or Sell Field Trip Health Stock? Get The Latest FTR Stock Analysis, Price Target, and Headlines at MarketBeat.